Safety and testing
Gaye Gardner made this Official Information request to Ministry of Health
This request has an unknown status. We're waiting for Gaye Gardner to read recent responses and update the status.
From: Gaye Gardner
Dear Ministry of Health,
My OIA asks how many if any, batches of C19 vaccine were evaluated by NZ authorities?
What studies have been carried out on mRNA vaccine breaking the blood brain barrier?
Request a Copy of the Risk Management Plan by sponsors for C19 vaccine
Does NZ review the supplied data components for C19 vaccine or the vaccine itself?
How does NZ evaluate the efficacy of transmission of C19 when transmission was never trialled?
Yours faithfully,
Gaye Gardner
From: OIA Requests
Link: [1]File-List
Link: [2]Preview
Link: [3]Edit-Time-Data
Link: [4]themeData
Link: [5]colorSchemeMapping
Kia ora Gaye,
Thank you for your request for official information. The reference number
for your request is: H2024047406
As required under the Official Information Act 1982, Manatū Hauora will
endeavour to respond to your request no later than 20 working days after
the day your request was received. If you'd like to calculate the
timeframe, you can use the Ombudsman's online calculator
here: [6]http://www.ombudsman.parliament.nz/
If you have any queries, please feel free to contact the OIA Services Team
on [7][email address]. If any additional factors come to light which
are relevant to your request, please do not hesitate to contact us so that
these can be taken into account.
Under section 28(3) of the Act you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [8][email address] or by calling 0800
802 602.
Ngā mihi
OIA Services Team
[9]Ministry of Health information releases
------------------- Original Message
show quoted sections
From: OIA Requests
Kia ora,
Thank you for your request for official information received on 25 July
2024 for:
“My OIA asks how many if any, batches of C19 vaccine were evaluated by NZ
authorities?
What studies have been carried out on mRNA vaccine breaking the blood
brain barrier?
Request a Copy of the Risk Management Plan by sponsors for C19 vaccine
Does NZ review the supplied data components for C19 vaccine or the vaccine
itself?
How does NZ evaluate the efficacy of transmission of C19 when transmission
was never trialled?”
We are contacting you to clarify the first section (in bold) of your
request.
Please clarify what information you are seeking in regards to
'evaluation'. Are you meaning evaluation of applications for vaccines? If
so, this process is set out here:
[1]www.medsafe.govt.nz/COVID-19/vaccine-approval-process.asp
We look forward to receiving your response.
Ngâ mihi
OIA Services Team
Manatû Hauora | Ministry of Health
M[2]inistry of Health information releases
U[3]nite against COVID-19
show quoted sections
References
Visible links
1. https://www.medsafe.govt.nz/COVID-19/vac...
2. https://www.health.govt.nz/about-ministr...
3. https://covid19.govt.nz/
From: OIA Requests
Tēnā koe Gaye
Thank you for your request under the Official Information Act 1982 (the
Act) to the Ministry of Health – Manatū Hauora (the Ministry) on 25 July
2024 for:
“My OIA asks how many if any, batches of C19 vaccine were evaluated by NZ
authorities?
Medicines are required to be approved before they are sold in New Zealand.
Medsafe does not evaluate batches as they are released in New Zealand.
Information on this process is available here:
www.medsafe.govt.nz/consumers/safety-of-...
What studies have been carried out on mRNA vaccine breaking the blood
brain barrier?
Medsafe does not carry out studies. Please refer to online scientific
studies for further information at: [1]https://pubmed.ncbi.nlm.nih.gov/.
Request a Copy of the Risk Management Plan by sponsors for C19 vaccine
Summaries of Risk Management Plans are publicly available here:
[2]www.medsafe.govt.nz/COVID-19/status-of-applications.asp.
Does NZ review the supplied data components for C19 vaccine or the vaccine
itself?
Medsafe is not aware of the term ‘supplied data components’. Information
on Medsafe’s approval and review processes is available here:
[3]www.medsafe.govt.nz/COVID-19/covid-landing.asp.
How does NZ evaluate the efficacy of transmission of C19 when transmission
was never trialled?”
Medsafe has not evaluated the efficacy of transmission, and as such, this
section of your request is refused under section 18(g)(i) of the Act as
the information requested does not exist.
If you wish to discuss any aspect of your request with us, including this
decision, please feel free to contact the OIA Services Team
on: [4][email address].
Under section 28(3) of the Act, you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [5][email address] or by calling 0800
802 602.
Ngā mihi
OIA Services Team
Manatū Hauora | Ministry of Health
M[6]inistry of Health information releases
U[7]nite against COVID-19
show quoted sections
References
Visible links
1. https://pubmed.ncbi.nlm.nih.gov/
2. https://www.medsafe.govt.nz/COVID-19/sta...
3. http://www.medsafe.govt.nz/COVID-19/covi...
4. mailto:[email address]
5. mailto:[email address]
6. https://www.health.govt.nz/about-ministr...
7. https://covid19.govt.nz/
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence